Hua Medicine announced additional analysis results from dorzagliatin's 24-week metformin combination registration trial DAWN, (also known as HMM0302). Findings from the DAWN study will be presented in oral and symposium presentations at the Chinese Diabetes Society's 2020 Scientific Meeting. The 24-week data indicates that, for Type 2 diabetes patients whose blood glucose cannot be controlled with the maximum tolerated dose of metformin (1,500mg/day), the dorzagliatin and metformin treatment group lowered HbA1c by 1.02%, superior over placebo treated group by 0.66% (placebo + metformin group reduced HbA1c by 0.36%). Dorzagliatin also demonstrated the below characteristics: Fast on-set of action (effective HbA1c reduction in 4 weeks); Significant improvement of -cell function and reduction of insulin resistance in treatment group as compared to the placebo group; Significant reduction of 2-hour post-prandial glucose reduction was observed in treatment group as compared to the placebo group; Good safety profile and tolerance of dorzagliatin with limited hypoglycemia (Less than 1% observed during 24-week treatment); Sustained efficacy over 24 weeks; Good response rate.